Crucell N.V. has entered into a co-exclusive PER.C6 and Advac technology license agreement with Wyeth. Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on product sales. Financial details were not disclosed.

AdVac technology is a recombinant vector technology used to develop adenoviral-based products. PER.C6 technology is based on a human cell line developed for the large-scale manufacture of biological products including vaccines.